Immune responses against the mutated region of cytoplasmatic NPM1 might contribute to the favorable clinical outcome of AML patients with NPM1 mutations (NPM1mut)

Blood. 2013 Aug 8;122(6):1087-8. doi: 10.1182/blood-2013-04-496844.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • CD8-Positive T-Lymphocytes / immunology
  • Cancer Vaccines / immunology
  • Cell Nucleus / metabolism
  • Cytoplasm / metabolism
  • Epitopes / immunology
  • Humans
  • Leukemia, Myeloid, Acute / genetics
  • Leukemia, Myeloid, Acute / immunology*
  • Mutation*
  • Nuclear Proteins / genetics*
  • Nuclear Proteins / immunology
  • Nucleophosmin
  • Peptides / immunology
  • Prognosis
  • Stem Cell Transplantation
  • Survival Analysis
  • Transplantation, Homologous
  • Treatment Outcome

Substances

  • Cancer Vaccines
  • Epitopes
  • NPM1 protein, human
  • Nuclear Proteins
  • Peptides
  • Nucleophosmin